Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1200-1210

  Lakshminarayana, Suresh B ^a   Freymond, Céline ^b,c   Fischli, Christoph ^b,c   Yu, Jing ^d   Weber, Sebastian ^e   Goh, Anne ^a   Yeung, Bryan K S ^a   Ho, Paul C ^f   Dartois, Véronique ^a,g   Diagana, Thierry T ^a   Rottmann, Matthias ^b,c   Blasco, Francesca ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; KAE 609; SPIRO COMPOUND; SPIROINDOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; ELIMINATION HALF-LIFE; FEMALE; IC50; IN VITRO STUDY; MALARIA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; PATHOGENICITY;

ANIMALS; ANTIMALARIALS; DISEASE MODELS, ANIMAL; FEMALE; MALARIA; MICE; PLASMODIUM BERGHEI;

EID: 84921926372     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03274-14     Document Type: Article

References (57)

1. Greenwood B, Mutabingwa T. 2002. Malaria in 2002. Nature 415:670-672. http://dx.doi.org/10.1038/415670a.
2. WHO. 2012. World malaria report. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/world-malaria -report-2012/wmr2012-no-profiles.pdf?ua=1.
3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431. http://dx.doi.org/10.1016/S0140-6736(12)60034-8.
4. White NJ. 2004. Antimalarial drug resistance. J Clin Invest 113:1084-1092. http://dx.doi.org/10.1172/JCI200421682.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria.NEngl J Med 361:455-467. http: //dx.doi.org/10.1056/NEJMoa0808859.
6. Ferreira PE, Culleton R, Gil J P, Meshnick SR. 2013. Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol 29:318-320. http://dx.doi.org/10.1016/j.pt.2013.05.002.
7. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimdé AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, et al. 2013. Multiple populations of artemisininresistant Plasmodium falciparum in Cambodia. Nat Genet 45:648-655. http://dx.doi.org/10.1038/ng.2624.
8. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
9. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10. http://dx.doi.org/10.1086/516284.
10. Craig WA. 2001. Does the dose matter? Clin Infect Dis 33(Suppl 3):S233-S237. http://dx.doi.org/10.1086/321854.
11. Scaglione F, Paraboni L. 2006. Influence of pharmacokinetics/ pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 4:479-490. http://dx.doi.org/10.1586/14787210.4.3.479.
12. Drusano GL. 2007. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 45(Suppl 1):589-595. http://dx.doi.org/10.1086 /518137.
13. Gautam A, Ahmed T, Batra V, Paliwal J. 2009. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab 10: 289-306. http://dx.doi.org/10.2174/138920009787846323.
14. Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ. 2006. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol 62: 1003-1009. http://dx.doi.org/10.1007/s00228-006-0203-2.
15. Barnes KI, Watkins WM, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol 24:127-134. http://dx.doi.org/10 .1016/j.pt.2007.11.008.
16. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP. 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8:253. http://dx.doi.org/10.1186/1475-2875-8-253.
17. Na-Bangchang K, Karbwang J. 2009. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam Clin Pharmacol 23:387-409. http://dx.doi.org/10 .1111/j.1472-8206.2009.00709.x.
18. Hoshen MB, Stein WD, Ginsburg HD. 2001. Pharmacokineticpharmacodynamic modelling of the antimalarial activity of mefloquine. Parasitology 123:337-346.
19. Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M. 2002. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 58:339-351. http://dx.doi.org/10.1007/s00228-002 -0485-y.
20. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. 2008. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol 24:159-163. http://dx.doi.org/10.1016/j.pt.2008 .01.006.
21. Ashley EA, Pinoges L, Turyakira E, Dorsey G, Checchi F, Bukirwa H, van den Broek I, Zongo I, Urruta PP, van Herp M, Balkan S, Taylor WR, Olliaro P, Guthmann JP. 2008. Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children. Malar J 7:154. http://dx.doi.org/10 .1186/1475-2875-7-154.
22. White NJ. 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18:458-464. http://dx.doi.org/10.1016/S1471-4922(02)02373-5.
23. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HLE, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drugresistant malaria. Antimicrob Agents Chemother 51:4090-4097. http: //dx.doi.org/10.1128/AAC.00486-07.
24. D'Alessandro U. 2009. Existing antimalarial agents and malariatreatment strategies. Expert Opin Pharmacother 10:1291-1306. http://dx .doi.org/10.1517/14656560902942319.
25. Hoshen MB, Stein WD, Ginsburg H. 2002. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 124:9-15. http://dx.doi.org/10.1017/S0031182001008952.
26. White NJ. 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41:1413-1422.
27. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. 2013. Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med 5:205ra135. http://dx.doi.org/10.1126 /scitranslmed.3006684.
28. White NJ. 2013. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother 57: 5792-5807. http://dx.doi.org/10.1128/AAC.00287-13.
29. Peters W, Robinson BL. 1999. Malaria, p 757-773. In Zak O, Sande M (ed), Handbook of animal models of infection. Academic Press, London, United Kingdom.
30. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 3:509-520. http://dx.doi.org/10.1038/nrd1416.
31. Jiménez-Díaz MB, Viera S, Ibáñez J, Mulet T, Magán-Marchal N, Garuti H, Gómez V, Cortés-Gil L, Martínez A, Ferrer S, Fraile MT, Calderón F, Fernández E, Shultz LD, Leroy D, Wilson DM, García-Bustos JF, Gamo FJ, Angulo-Barturen I. 2013. A new in vivo screening paradigm to accelerate antimalarial drug discovery. PLoS One 8:e66967. http://dx.doi.org/10.1371/journal.pone.0066967.
32. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175-1180. http: //dx.doi.org/10.1126/science.1193225.
33. Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. 2010. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 53:5155-5164. http://dx.doi.org/10.1021/jm100410f.
34. Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K. 2013. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13:227-237. http: //dx.doi.org/10.1016/j.chom.2012.12.006.
35. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675. http://dx.doi.org/10.1126/science.781840.
36. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 16:710-718. http://dx .doi.org/10.1128/AAC.16.6.710.
37. Stan Development Team. 2014. Stan version 2.1. http://mc-stan.org/.
38. Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M, Kamber J, Meyer S, Papastogiannidis P, Siegrist R, Voss T, Welford R, Wittlin S, Binkert C. 2012. Identification of a new chemical class of antimalarials. J Infect Dis 206:735-743. http://dx.doi.org/10.1093/infdis/jis418.
39. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M, van der Linden R, Sinden RE, Waters AP, Janse CJ. 2004. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem 137:23-33. http://dx.doi .org/10.1016/j.molbiopara.2004.04.007.
40. Silber HE, Burgener C, Letellier IM, Peyrou M, Jung M, King JN, Gruet P, Giraudel JM. 2010. Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharm Res 27:2633-2645. http://dx.doi.org/10 .1007/s11095-010-0262-z.
41. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. 2000. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 44:1247-1254. http://dx.doi.org/10.1128/AAC.44.5 .1247-1254.2000.
42. Sinou V, Taudon N, Mosnier J, Aglioni C, Bressolle FM, Parzy D. 2008. Pharmacokinetics of artesunate in the domestic pig. J Antimicrob Chemother 62:566-574. http://dx.doi.org/10.1093/jac/dkn231.
43. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55: 601-607. http://dx.doi.org/10.1093/jac/dki079.
44. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect 44:79-86. http: //dx.doi.org/10.1086/510079.
45. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat Rev Microbiol 2:289-300. http://dx.doi.org /10.1038/nrmicro862.
46. Scaglione F, Mouton JW, Mattina R, Fraschini F. 2003. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother 47:2749-2755. http://dx.doi.org/10.1128/AAC .47.9.2749-2755.2003.
47. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 2011. Protein binding: do we ever learn? Antimicrob Agents Chemother 55: 3067-3074. http://dx.doi.org/10.1128 /AAC.01433-10.
48. Weiss HM, Gatlik E. 2014. Equilibrium gel filtration to measure plasma protein binding of very highly bound drugs. J Pharm Sci 103:752-759. http://dx.doi.org/10.1002/jps.23818.
49. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N -desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 1444-1451. http://dx.doi .org/10.1128/AAC.00720-11.
50. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FCK, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL. 2011. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 108:4400-4405. http: //dx.doi.org/10.1073/pnas.1015762108.
51. Patel K, Batty KT, Moore BR, Gibbons PL, Bulitta JB, Kirkpatrick CM. 2013. Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria. Antimicrob Agents Chemother 57:508-516. http://dx.doi.org/10.1128/AAC.01463-12.
52. Gibbons PL, Batty KT, Barrett PH, Davis TM, Ilett KF. 2007. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Int J Parasitol 37:1569. http://dx.doi .org/10.1016/j.ijpara.2007.05.001.
53. Moore BR, Batty KT, Andrzejewski C, Jago JD, Page-Sharp M, Ilett KF. 2008. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother 52:306-311. http://dx .doi.org/10.1128/AAC.00878-07.
54. Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, Batty KT. 2011. Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother 55: 3899-3907. http://dx.doi.org/10.1128/AAC.00067-11.
55. Batty KT, Gibbons PL, Davis TM, Ilett KF. 2008. Pharmacokinetics of dihydroartemisinin in a murine malaria model. Am J Trop Med Hyg 78: 641-642.
56. Bouzom F, Laveille C, Merdjan H, Jochemsen R. 2000. Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat. J Pharm Sci 8:603-613. http: //dx.doi.org/10.1002/(SICI)1520-6017(200005)89:5-603::AID-JPS6 3 .0.CO;2-E.
57. White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefèvre G, Li R, Magnusson B, Diagana TT, Leong FJ. 2014. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 371: 403-410. http://dx.doi.org/10 .1056/NEJMoa1315860.